OBJECTIVE: Familial Mediterranean fever (FMF) is an autosomal-recessive disorder that is common in Armenian, Turkish, Arab, and Sephardic Jewish populations. Its clinical diagnosis is one of exclusion, with the patients displaying nonspecific symptoms related to serosal inflammation. MEFV gene analysis has provided the first objective diagnostic criterion for FMF. However, in the absence of an identified mutation (NI/NI genotype), both the sensitivity of the molecular analyses and the involvement of the MEFV gene in FMF are called into question. The present study was designed to further evaluate the diagnostic value of MEFV analysis in another population of Mediterranean extraction. METHODS: The MEFV gene was screened for mutations in 50 patients living in Karabakh (near Armenia) who fulfilled the established criteria for FMF. In addition, we analyzed published series of patients from the above-mentioned at-risk populations. RESULTS: The mutation spectrum in Karabakhian patients, which consisted of only 6 mutations (with 26% of NI alleles), differed from that reported in Armenian patients. Strikingly, among patients from Karabakh and among all classically affected populations, the distribution of genotypes differed dramatically from Hardy-Weinberg equilibrium (P = 0.0016 and P < 0.00001, respectively). These results, combined with other population genetics-based data, revealed the existence of an FMF-like condition that, depending on the patients' ancestry, was shown to affect 85-99% of those with the NI/NI genotype. CONCLUSION: These data illuminate the meaning of negative results of MEFV analyses and show that in all populations evaluated, most patients with the NI/NI genotype had disease that mimicked FMF and was unrelated to the MEFV gene. Our findings also demonstrate the high sensitivity of a search for very few mutations in order to perform a molecular diagnosis of MEFV-related FMF.
OBJECTIVE:Familial Mediterranean fever (FMF) is an autosomal-recessive disorder that is common in Armenian, Turkish, Arab, and Sephardic Jewish populations. Its clinical diagnosis is one of exclusion, with the patients displaying nonspecific symptoms related to serosal inflammation. MEFV gene analysis has provided the first objective diagnostic criterion for FMF. However, in the absence of an identified mutation (NI/NI genotype), both the sensitivity of the molecular analyses and the involvement of the MEFV gene in FMF are called into question. The present study was designed to further evaluate the diagnostic value of MEFV analysis in another population of Mediterranean extraction. METHODS: The MEFV gene was screened for mutations in 50 patients living in Karabakh (near Armenia) who fulfilled the established criteria for FMF. In addition, we analyzed published series of patients from the above-mentioned at-risk populations. RESULTS: The mutation spectrum in Karabakhian patients, which consisted of only 6 mutations (with 26% of NI alleles), differed from that reported in Armenian patients. Strikingly, among patients from Karabakh and among all classically affected populations, the distribution of genotypes differed dramatically from Hardy-Weinberg equilibrium (P = 0.0016 and P < 0.00001, respectively). These results, combined with other population genetics-based data, revealed the existence of an FMF-like condition that, depending on the patients' ancestry, was shown to affect 85-99% of those with the NI/NI genotype. CONCLUSION: These data illuminate the meaning of negative results of MEFV analyses and show that in all populations evaluated, most patients with the NI/NI genotype had disease that mimicked FMF and was unrelated to the MEFV gene. Our findings also demonstrate the high sensitivity of a search for very few mutations in order to perform a molecular diagnosis of MEFV-related FMF.
Authors: D O Tchernitchko; M Gérard-Blanluet; M Legendre; C Cazeneuve; G Grateau; S Amselem Journal: Ann Rheum Dis Date: 2006-01-26 Impact factor: 19.103
Authors: K Migita; K Agematsu; K Yamazaki; A Suzuki; M Yazaki; Y Jiuchi; T Miyashita; Y Izumi; T Koga; A Kawakami; K Eguchi Journal: Clin Exp Immunol Date: 2011-03-25 Impact factor: 4.330
Authors: Jae Jin Chae; Geryl Wood; Katharina Richard; Howard Jaffe; Nona T Colburn; Seth L Masters; Deborah L Gumucio; Nitza G Shoham; Daniel L Kastner Journal: Blood Date: 2008-06-24 Impact factor: 22.113
Authors: I Jéru; P Duquesnoy; T Fernandes-Alnemri; E Cochet; J W Yu; M Lackmy-Port-Lis; E Grimprel; J Landman-Parker; V Hentgen; S Marlin; K McElreavey; T Sarkisian; G Grateau; E S Alnemri; S Amselem Journal: Proc Natl Acad Sci U S A Date: 2008-01-29 Impact factor: 11.205
Authors: Matthew G Booty; Jae Jin Chae; Seth L Masters; Elaine F Remmers; Beverly Barham; Julie M Le; Karyl S Barron; Steve M Holland; Daniel L Kastner; Ivona Aksentijevich Journal: Arthritis Rheum Date: 2009-06